• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项基于美国食品药品监督管理局不良事件报告系统的曲唑酮真实世界药物警戒研究。

A realworld pharmacovigilance study of trazodone based on the FDA adverse event reporting system.

作者信息

Yu Yong, Sun Xin, Hao Liqun, Zhang Xiaoyan, Guo Yankui

机构信息

The First Clinical College of Medicine, Shandong University of Traditional Chinese Medicine, Jinan, 250013, Shandong Province, China.

Jinan Hospital of Guang an men Hospital, China Academy of Chinese Medical Sciences, Jinan, 250012, Shandong Province, China.

出版信息

Sci Rep. 2025 Feb 13;15(1):5322. doi: 10.1038/s41598-025-89632-7.

DOI:10.1038/s41598-025-89632-7
PMID:39948419
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11825867/
Abstract

To explore and analyze the potential adverse event (AE) signals of trazodone, with reference to the safe clinical use of drugs. Based on the FDA Adverse Event Reporting System (FAERS), the AE data of trazodone were extracted from the first quarter of 2004 to the second quarter of 2024, and the extracted data were statistically analyzed using the method, to identify valid AE signals that met our judgment, compare them with those recorded in the authorized information for trazodone thereby identifying unexpected potential adverse reactions. A total of 5199 AE reports with trazodone as the main suspect were extracted, with a higher reported proportion of females (52.68%) than males (38.83%). Many reports (31.47%) did not provide age information, although for those reports with identifiable age data, the 50-60 years age group was the most common (14.20%), and the country of reporting was predominantly the United States (82.58%). A total of 179 significant AE signals were unearthed, with suicide, formulation toxicity, abnormal penile erection, insomnia, and cardiac and respiratory arrest reported with high frequency, which was not entirely consistent with the specification record. The study unearthed 156 new potential AEs on the basis of trazodone drug inserts and suggested precautions for overdosing and dose adjustment, which is conducive to safeguarding the safety of patients' medication.

摘要

为参照药物临床安全使用情况,探索并分析曲唑酮潜在的不良事件(AE)信号。基于美国食品药品监督管理局不良事件报告系统(FAERS),提取2004年第一季度至2024年第二季度曲唑酮的AE数据,并采用该方法对提取的数据进行统计分析,以识别符合我们判断标准的有效AE信号,将其与曲唑酮批准信息中记录的信号进行比较,从而识别出意外的潜在不良反应。共提取了5199份以曲唑酮为主要怀疑对象的AE报告,报告中女性比例(52.68%)高于男性(38.83%)。许多报告(31.47%)未提供年龄信息,不过对于那些有可识别年龄数据的报告,50 - 60岁年龄组最为常见(14.20%),报告国家主要为美国(82.58%)。共发现179个显著的AE信号,其中自杀、制剂毒性、阴茎异常勃起、失眠以及心脏和呼吸骤停报告频率较高,这与说明书记录并不完全一致。该研究在曲唑酮药品说明书基础上发现了156个新的潜在AE,并提出了过量用药和剂量调整的建议,这有助于保障患者用药安全。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f12b/11825867/45ca1252daac/41598_2025_89632_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f12b/11825867/4c28329283d3/41598_2025_89632_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f12b/11825867/45ca1252daac/41598_2025_89632_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f12b/11825867/4c28329283d3/41598_2025_89632_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f12b/11825867/45ca1252daac/41598_2025_89632_Fig2_HTML.jpg

相似文献

1
A realworld pharmacovigilance study of trazodone based on the FDA adverse event reporting system.一项基于美国食品药品监督管理局不良事件报告系统的曲唑酮真实世界药物警戒研究。
Sci Rep. 2025 Feb 13;15(1):5322. doi: 10.1038/s41598-025-89632-7.
2
The drug risks of cilostazol: A pharmacovigilance study of FDA Adverse Event Reporting System database.西洛他唑的药物风险:一项对美国食品药品监督管理局不良事件报告系统数据库的药物警戒研究。
PLoS One. 2024 Dec 4;19(12):e0314957. doi: 10.1371/journal.pone.0314957. eCollection 2024.
3
Multidimensional assessment of adverse events of finasteride:a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024.非那雄胺不良事件的多维评估:基于2004年至2024年4月美国食品药品监督管理局不良事件报告系统(FAERS)的真实世界药物警戒分析
PLoS One. 2025 Mar 24;20(3):e0309849. doi: 10.1371/journal.pone.0309849. eCollection 2025.
4
A real-world pharmacovigilance study of netarsudil based on the FDA adverse event reporting system (FAERS).一项基于美国食品药品监督管理局不良事件报告系统(FAERS)的奈他地尔真实世界药物警戒研究。
BMC Pharmacol Toxicol. 2025 Apr 21;26(1):88. doi: 10.1186/s40360-025-00927-x.
5
A pharmacovigilance analysis of abrocitinib-related skin adverse events based on the FDA Adverse Event Reporting System (FAERS).基于美国食品药品监督管理局不良事件报告系统(FAERS)的阿巴西普相关皮肤不良事件的药物警戒分析。
Arch Dermatol Res. 2025 Feb 15;317(1):419. doi: 10.1007/s00403-025-03959-9.
6
Post-marketing safety concerns with rimegepant based on a pharmacovigilance study.基于药物警戒研究的利马曲班的上市后安全性关注。
J Headache Pain. 2024 Oct 7;25(1):169. doi: 10.1186/s10194-024-01858-4.
7
Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.他法米替尼的安全性评估:FDA 不良事件报告系统(FAERS)事件的真实世界药物警戒研究。
BMC Pharmacol Toxicol. 2024 Sep 27;25(1):71. doi: 10.1186/s40360-024-00790-2.
8
A Real-World Pharmacovigilance Study of FDA Adverse Event Reporting System Events for Obeticholic Acid.一项关于奥贝胆酸的美国食品药品监督管理局不良事件报告系统事件的真实世界药物警戒研究。
Pharmacoepidemiol Drug Saf. 2025 Jan;34(1):e70084. doi: 10.1002/pds.70084.
9
A post-marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database.阿伐替尼上市后药物警戒研究:基于美国食品药品监督管理局不良事件报告系统数据库的不良事件数据挖掘与分析。
Br J Clin Pharmacol. 2024 Aug;90(8):1816-1826. doi: 10.1111/bcp.15673. Epub 2023 Feb 6.
10
Post-marketing pharmacovigilance study of inclisiran: mining and analyzing adverse event data from the FDA Adverse Event Reporting System database.依洛尤单抗的上市后药物警戒研究:从 FDA 不良事件报告系统数据库中挖掘和分析不良事件数据。
Int J Clin Pharm. 2024 Dec;46(6):1419-1426. doi: 10.1007/s11096-024-01784-0. Epub 2024 Aug 27.

本文引用的文献

1
Real-World Use of Trazodone in Older Persons in Long Term Care Setting: A Retrospective Study.真实世界中曲唑酮在长期护理环境下老年患者中的应用:一项回顾性研究。
Int J Geriatr Psychiatry. 2024 Nov;39(11):e70009. doi: 10.1002/gps.70009.
2
The evolving role of disproportionality analysis in pharmacovigilance.药物警戒中比例失衡分析的作用演变。
Expert Opin Drug Saf. 2024 Aug;23(8):981-994. doi: 10.1080/14740338.2024.2368817. Epub 2024 Jun 24.
3
Rethinking the role of trazodone in the different depressive dimensions.重新思考曲唑酮在不同抑郁维度中的作用。
Expert Rev Neurother. 2024 Jul;24(7):619-632. doi: 10.1080/14737175.2024.2363843. Epub 2024 Jun 17.
4
Trazodone-related oromandibular dyskinesia.曲唑酮相关的口下颌运动障碍。
J Family Med Prim Care. 2024 Mar;13(3):1103-1105. doi: 10.4103/jfmpc.jfmpc_645_23. Epub 2024 Apr 4.
5
Treatment-Resistant Priapism in a 61-Year-Old Male After Combined Use of Trazodone, Quetiapine, and Fluoxetine.一名61岁男性在联合使用曲唑酮、喹硫平和氟西汀后出现难治性阴茎异常勃起
J Clin Psychopharmacol. 2024;44(3):316-317. doi: 10.1097/JCP.0000000000001832. Epub 2024 Apr 18.
6
Safety assessment of cenobamate: real-world adverse event analysis from the FAERS database.司替戊醇的安全性评估:来自FAERS数据库的真实世界不良事件分析。
Front Pharmacol. 2024 Mar 15;15:1369384. doi: 10.3389/fphar.2024.1369384. eCollection 2024.
7
Multidimensional assessment of adverse events of bupropion: A large-scale data analysis from the FAERS database.多维度评估安非他酮的不良事件:来自 FAERS 数据库的大规模数据分析。
J Affect Disord. 2024 Jun 1;354:649-655. doi: 10.1016/j.jad.2024.03.085. Epub 2024 Mar 15.
8
Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data.生物制剂治疗银屑病的主要心血管事件:FAERS 数据的 19 年真实世界分析。
Front Immunol. 2024 Feb 7;15:1349636. doi: 10.3389/fimmu.2024.1349636. eCollection 2024.
9
Trazodone Overdose Manifesting as Hypotension and QT Prolongation.曲唑酮过量表现为低血压和QT间期延长。
Cureus. 2023 Mar 29;15(3):e36871. doi: 10.7759/cureus.36871. eCollection 2023 Mar.
10
Tardive Oromandibular Dystonia Induced by Trazodone: A Clinical Case and Management from the Perspective of the Dental Specialist.曲唑酮致迟发性口颌肌张力障碍:从口腔专家角度看临床病例及处理方法。
Toxins (Basel). 2022 Sep 30;14(10):680. doi: 10.3390/toxins14100680.